Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DIAPH2 antisense RNA 1 (DIAPH2-AS1)
- Target
- DIAPH2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
DIAPH2 antisense RNA 1 (DIAPH2-AS1) is a long non-coding RNA gene expressed in humans, located on the X chromosome. It does not encode a protein. Recent research indicates DIAPH2-AS1 acts as an oncogenic lncRNA in gastric cancer, particularly promoting neural invasion, cell migration, and invasion. Mechanistically, DIAPH2-AS1 interacts with the RNA-binding protein NSUN2, stabilizing it by preventing ubiquitin-proteasome-mediated degradation. NSUN2 in turn enhances the stability of NTN1 mRNA via m5C modification, promoting tumor progression. DIAPH2-AS1 is also reported to function as an early signal in T-cell activation, suggesting a role in immune response. There are no known approved drugs that directly target DIAPH2-AS1 itself, and it is not classified as a receptor, enzyme, or transporter, but rather as a regulatory non-coding RNA of emerging clinical interest in oncology and immunology[1][3][5].
- Other names
- DIAPH2 antisense gene protein 1EPAGEarly lymphoid activation gene proteinEarly lymphoid activation proteinDIAPH2-AS1 (non-protein coding)
02
Mechanism of action
Not applicable (no drugs currently target this lncRNA)
03
Biological functions
Regulation of cell migrationRegulation of cell invasionNeural invasion in cancerRegulation of RNA-binding proteinsEarly signal for T-cell activationSignal transduction
04
Disease associations
Cancer (especially gastric cancer)Potentially other roles in lymphoid activation
05
Biomarkers
Potential diagnostic biomarker for neural invasion-positive gastric cancer[1]
Beyond the preview
Go deeper on DIAPH2 antisense RNA 1 (DIAPH2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIAPH2 antisense RNA 1 (DIAPH2-AS1).